Bemarituzumab
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applications of Bemarituzumab in cancer research.
Product Specifications
CAS Number
1952272-74-0
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
FGFR
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6011651-01 0.05 mg
NFkB, p50, p105, phosphorylated (Ser907) (Nuclear Factor NF-kappa-B p105 Subunit, DNA-binding Factor KBF1, EBP-1, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-cells 1, Nuclear Factor NF-kappa-B p50 Subunit, NFKB1)
Ask
View Details 
MBS6011651-02 0.1 mg
NFkB, p50, p105, phosphorylated (Ser907) (Nuclear Factor NF-kappa-B p105 Subunit, DNA-binding Factor KBF1, EBP-1, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-cells 1, Nuclear Factor NF-kappa-B p50 Subunit, NFKB1)
Ask
View Details MBS6011651-03 5x 0.1 mg
NFkB, p50, p105, phosphorylated (Ser907) (Nuclear Factor NF-kappa-B p105 Subunit, DNA-binding Factor KBF1, EBP-1, Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-cells 1, Nuclear Factor NF-kappa-B p50 Subunit, NFKB1)
Ask
View Details MBS1387706-01 0.02 mg (E-Coli)
Recombinant Tropheryma whipplei Adenylate kinase (adk)
Ask
View Details 
MBS1387706-02 0.1 mg (E-Coli)
Recombinant Tropheryma whipplei Adenylate kinase (adk)
Ask
View Details